4.7 Article

Second Cancers After Squamous Cell Carcinoma and Adenocarcinoma of the Cervix

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 27, Issue 6, Pages 967-973

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2008.18.4549

Keywords

-

Categories

Funding

  1. Intramural Research Program
  2. National Cancer Institute
  3. National Institutes of Health

Ask authors/readers for more resources

Purpose Although cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) are both caused by human papillomavirus (HPV) infection, they differ in cofactors such as cigarette smoking. We assessed whether these cofactor differences translate into differences in second cancer risk. Patients and Methods We assessed second cancer risk among 85,109 cervical SCC and 10,280 AC survivors reported to population-based cancer registries in Denmark, Finland, Norway, Sweden, and the United States. Risks compared to the general population were assessed using standardized incidence ratios (SIR). Results Overall cancer risk was significantly increased among both cervical SCC survivors (n = 10,559 second cancers; SIR, 1.31; 95% CI, 1.29 to 1.34) and AC survivors (n = 920 second cancers; SIR, 1.29; 95% CI, 1.22 to 1.38). Risks of HPV-related and radiation-related cancers were increased to a similar extent among cervical SCC and AC survivors. Although significantly increased in both groups when compared with the general population, risk of smoking-related cancers was significantly higher among cervical SCC than AC survivors (P = .015; SIR for cervical SCC = 2.07 v AC = 1.78). This difference was limited to lung cancer (SIR for cervical SCC = 2.69 v AC = 2.18; P = .026). The increased lung cancer risk among cervical AC survivors was observed for both lung SCC and lung AC. SIRs for second cancers of the colon, soft tissue, melanoma, and non-Hodgkin's lymphoma were significantly higher among cervical AC than SCC survivors. Conclusion The second cancer profiles among cervical SCC and AC survivors mirror the similarities and differences in cofactors for these two histologies. Because smoking is not a cofactor for cervical AC, the increased lung cancer risk suggests a role for additional factors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

Monica S. Sierra, Sabrina H. Tsang, Carolina Porras, Rolando Herrero, Joshua N. Sampson, Bernal Cortes, John Schussler, Sarah Wagner, Loretto Carvajal, Wim Quint, Aimee R. Kreimer, Shangying Hu, Ana Cecilia Rodriguez, Byron Romero, Allan Hildesheim

Summary: This study estimated the prevalence and incidence of HPV infections in young adult women. The results showed that the incidence of HPV infections peaked at age 20 and steadily declined with age. The study also found that the incidence of HPV infections peaked within a year after first sexual intercourse and decreased over time. These findings suggest that HPV vaccination could be beneficial for young adult women in preventing cervical cancer and precancerous lesions.

SEXUALLY TRANSMITTED INFECTIONS (2023)

Article Oncology

From Nuclear Reactor-Based to Proton Accelerator-Based Therapy: The Finnish Boron Neutron Capture Therapy Experience

Liisa Porra, Lauri Wendland, Tiina Seppala, Hanna Koivunoro, Hannu Revitzer, Jussi Tervonen, Leena Kankaanranta, Anu Anttonen, Mikko Tenhunen, Heikki Joensuu

Summary: The authors reviewed the results of 249 patients treated with boron neutron capture therapy (BNCT) at Helsinki University Hospital, Finland. They found that BNCT using l-boronophenylalanine-fructose (l-BPA-F) as the boron delivery agent was well tolerated and showed efficacy in the treatment of head and neck cancer and malignant glioma. They also described a new hospital BNCT facility that integrates a proton accelerator-based neutron source for treatment planning and positioning.

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2023)

Article Oncology

Exclusive use of different types of tobacco products, exposure to secondhand tobacco smoke and risk of subtypes of head and neck cancer among Indian males

Devyani Gholap, Rajesh Dikshit, Pankaj Chaturvedi, Anil K. Chaturvedi, Ankita Manjrekar, Sharayu Mhatre

Summary: This study found a strong association between the exclusive use of smokeless tobacco products and the risk of various subtypes of head and neck cancer (HNC) in India. Chewing gutka had the highest risk, followed by betel quid with tobacco, tobacco quid, Khaini, Mawa, and Mishri. Bidi smoking and exposure to secondhand smoke were also independently associated with an increased risk of HNC. This suggests that tobacco control policies should focus on raising awareness about the risks of different tobacco products and emphasize that switching between types is not a safe alternative to quitting completely.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Trends in incidence rates of head and neck squamous cell carcinomas overall and by potential relatedness to human papillomavirus, Costa Rica 2006 to 2015

Loretto J. Carvajal, Jaimie Z. Shing, Juan C. Vanegas, Emmanuel Gonzalez, Diego Guillen, Monica S. Sierra, Allan Hildesheim, Carolina Porras, Rolando Herrero, Guillermo Torres, Meredith S. Shiels, Alejandro Calderon, Aimee R. Kreimer

Summary: This study investigated the incidence and trends of head and neck cancer in Costa Rica, specifically focusing on the potentially human papillomavirus (HPV)-related and HPV-unrelated head and neck squamous cell carcinomas (HNSCC). The findings showed a decreasing incidence of HNSCC overall, but an increasing trend for HPV-related HNSCCs. This study is important for understanding the epidemiology of head and neck cancer and the impact of HPV.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Pharmacology & Pharmacy

Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting

Jouko Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Hakkinen, Johanna Tervapuro, Hertta Pihlasvaara, Christophe Drieu La Rochelle, Heikki Joensuu

Summary: Ocular administration of palonosetron as eye drops can effectively prevent and treat nausea and vomiting. This method provides a quick and convenient way to deliver the medication when intravenous administration is not possible.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Article Oncology

Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions

W. K. Jacky Lam, Ann D. King, Jacob A. Miller, Zhiwei Liu, Kelly J. Yu, Melvin L. K. Chua, Brigette B. Y. Ma, Ming Yuan Chen, Benjamin A. Pinsky, Pei-Jen Lou, John K. S. Woo, Wan-Lun Hsu, Julia Simon, Denise L. Doolan, Tim Waterboer, Edwin P. Hui, Hui Li, Raymond K. Tsang, Kenneth C. W. Wong, Julian P. Goh, Alexander C. Vlantis, Qi Yong Ai, Lun M. Wong, Victor Abdullah, Jin Ching Lin, Chien-Jen Chen, Ruth M. Pfeiffer, Quynh-Thu Le, Anne W. M. Lee, Mingfang Ji, Sumei Cao, Jun Ma, Anthony T. C. Chan, K. C. Allen Chan, Allan Hildesheim

Summary: A meeting of experts in November 2021 discussed the performance and cost-effectiveness of EBV-based approaches for screening early stage nasopharyngeal carcinoma. Both serum EBV antibody and plasma EBV DNA testing methods were found to be favorable. Additionally, the use of MRI was recommended to increase the sensitivity of NPC detection without greatly impacting the cost-effectiveness of the screening program.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Oral microbiome and risk of incident head and neck cancer: A nested case-control study

Zeni Wu, Yongli Han, Yunhu Wan, Xing Hua, Samantha S. Chill, Kedest Teshome, Weiyin Zhou, Jia Liu, Dongjing Wu, Amy Hutchinson, Kristine Jones, Casey L. Dagnall, Belynda D. Hicks, Linda Liao, Heather Hallen-Adams, Jianxin Shi, Christian C. Abnet, Rashmi Sinha, Anil Chaturvedi, Emily Vogtmann

Summary: This study found a relationship between oral microbiome and head and neck cancer. The presence of multiple microbial species, including periodontal pathogens, as well as higher microbial alpha-diversity and the presence of oral fungi, were associated with reduced risk of HNC. Larger studies are needed to further evaluate these associations.

ORAL ONCOLOGY (2023)

Article Oncology

Do investments in cancer registry databases and tools bring added value? NORDCAN as an example

Hans Henrik Storm, Siri Laronningen, Freddie Bray

Summary: The KIN project provided timely cancer statistics for cancer control planning in the Nordic countries, and the development of NORDCAN project reduced investment costs and increased scientific value.

ACTA ONCOLOGICA (2023)

Article Oncology

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, Jochen Schuette, Silke Cameron, Peter Hohenberger, Harri Sihto, Philipp J. Jost, Lars H. Lindner, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Tommi Pesonen, Peter Reichardt

Summary: This study found that patients with KIT exon 11 deletion/indel mutation in gastrointestinal stromal tumor (GIST) had longer overall survival (OS) and recurrence-free survival (RFS) when treated with 3 years of adjuvant imatinib compared to 1 year of treatment. However, patients with KIT exon 9 mutation had poor OS regardless of the duration of adjuvant imatinib treatment.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV cohort studies

Jessica L. Petrick, Andrea A. Florio, Jane Zen, Yanyu Wang, Andrew T. Gewirtz, Ruth M. Pfeiffer, Sarah Loftus, Jon Inglefield, Jill Koshiol, Baiyu Yang, Kelly Yu, Allan Hildesheim, Chien-Jen Chen, Hwai- Yang, Mei-Hsuan Lee, Katherine A. McGlynn

Summary: Research findings suggest that gut barrier dysfunction may lead to liver exposure to bacterial products from the gut, promoting liver diseases such as hepatitis and hepatocellular carcinoma. This study investigated the association between biomarkers of gut barrier dysfunction and HCC risk in HBV/HCV carriers. The results showed that a doubling of antiflagellin IgA or LBP levels in the blood was associated with a significantly increased risk of HBV-related HCC, while other markers did not show the same association.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Biochemistry & Molecular Biology

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer

Kaisa Lehtomaki, Eetu Heerva, Pirkko-Liisa Kellokumpu-Lehtinen, Harri Mustonen, Tapio Salminen, Heikki Joensuu, Kethe Hermunen, Mogens Karsbol Boisen, Julia Sidenius Johansen, Caj Haglund, Pia Osterlund

Summary: Based on the analysis of clinical data from patients with colorectal cancer undergoing adjuvant chemotherapy, it was found that CEA levels transiently increased in about half of the patients during the treatment. Compared to patients with a persistent increase, those with transiently increased CEA had better outcomes in terms of disease-free survival and overall survival.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Multidisciplinary Sciences

Academic achievement after a CT examination toward the head in childhood: Follow up of a randomized controlled trial

Elina Salonen, Robert Bujila, Jean-Luc af Geijerstam, Hakan Nyman, Olof Flodmark, Peter Aspelin, Magnus Kaijser

Summary: This study examined whether the ionizing radiation dose from a CT head scan at the age of 6-16 years affects academic performance and high school eligibility. The results showed no statistically significant differences between the exposed and unexposed participants in any of the variables studied.

PLOS ONE (2023)

Article Oncology

HER2A16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer

Sherif Samer Attalla, Jonathan Boucher, Hailey Proud, Tarek Taifour, Dongmei Zuo, Virginie Sanguin-Gendreau, Chen Ling, Gabriella Johnson, Vincent Li, Robin B. Luo, Hellen Kuasne, Vasilios Papavasiliou, Logan A. Walsh, Mark Barok, Heikki Joensuu, Morag Park, Philippe P. Roux, William J. Muller

Summary: The tumor-immune microenvironment (TIME) plays a crucial role in therapeutic response, and this study reveals the association of HER2A16 variant with poor clinical outcome in breast cancer and the immune cold phenotype of HER2A16 tumors. ENPP1 is identified as a functional regulator of the immune cold microenvironment, and targeting ENPP1 may have therapeutic potential in aggressive HER2 positive breast cancer.

CANCER IMMUNOLOGY RESEARCH (2023)

Article Gastroenterology & Hepatology

Genome-Wide Association Study Identifies 4 Novel Risk Loci for Small Intestinal Neuroendocrine Tumors Including a Missense Mutation in LGR5

Anil K. Giri, Mervi Aavikko, Linnea Wartiovaara, Toni Lemmetyinen, Juha Karjalainen, Juha Mehtonen, Kimmo Palin, Niko Valimaki, Max Tamlander, Riikka Saikkonen, Auli Karhu, Ekaterina Morgunova, Benjamin Sun, Heiko Runz, Priit Palta, Shuang Luo, Heikki Joensuu, Tomi P. Makela, Iiro Kostiainen, Camilla Schalin-Jantti, Aarno FinnGen, Aarno Palotie, Lauri A. Aaltonen, Saara Ollila, Mark J. Daly

Summary: This study is the largest genome-wide association study on small intestinal neuroendocrine tumors (SI-NETs) to date, and it identified 6 significant loci associated with SI-NET risk. Four of these loci are novel, and one of the top hits is a missense variant in the LGR5 gene, a marker of adult intestinal stem cells.

GASTROENTEROLOGY (2023)

Review Oncology

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib

Heikki Joensuu

Summary: Gastrointestinal stromal tumor (GIST) is a common sarcoma arising from the gastrointestinal tract, mainly the stomach, with varying malignancy potential. Surgery is generally curative for localized GISTs. Adjuvant imatinib has been shown to improve recurrence-free survival and overall survival (OS) in high-risk GIST patients with an imatinib-sensitive mutation.

CANCERS (2023)

No Data Available